A Multicenter, Randomized, Placebo-Controlled Trial of Prophylactic Recombinant Granulocyte-Colony Stimulating Factor in Preterm Neonates with Neutropenia

Kuhn, Pierre; Messer, J; Paupe, A; Espagne, Sandrine; Kacet, N.; Mouchnino, G; Klosowski, S; Krim, G; Lescure, Sandra; Bouédec, S. Le; Meyer, Pierre; Astruc, Dominique

doi:10.1016/j.jpeds.2009.03.019

Cited by 55 publications

(28 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One should keep in mind that resistance to G-CSF in NAIN associated with anti-HNA-2 antibodies, possibly due to a G-CSF-induced increase of HNA-2 expression on the neutrophils, has been described [63,64,65]. Despite the stimulated production of neutrophils, controversial results on the benefit of G-CSF in terms of infection-free survival have been published [66,67,68,69,70]. …”

Section: Treatmentmentioning

confidence: 99%

Neonatal Alloimmune Neutropenia

Porcelijn

Haas

2018

Transfus Med Hemother

View full text Add to dashboard Cite

Neonatal alloimmune neutropenia (NAIN, NAIN or NIN) is a neutrophil blood group antagonism, analogous to hemolytic disease of the fetus and newborn (HDFN) and fetal/neonatal alloimmune thrombocytopenia (FNAIT). A limited number of prospective screening studies showed that granulocyte-specific antibodies were detectable in 0.35-1.1% of random postnatal maternal samples and that the incidence of NAIN was below 0.1%. Symptoms vary from none to mild skin infections, omphalitis or more severe infections like pneumonia, sepsis, and meningitis. Treatment of neonatal infection with antibiotics and granulocyte-colony stimulating factor is advised.

show abstract

Section: Treatmentmentioning

confidence: 99%

Neonatal Alloimmune Neutropenia

Porcelijn

Haas

2018

Transfus Med Hemother

View full text Add to dashboard Cite

show abstract

“…In a simultaneous French study, 200 preterm infants with established neutropenia (<1.5×10 9 /l), persisting over 24 h within 3 weeks from birth, were randomised between G-CSF or placebo intravenous for 3 days. There was no significant difference between groups for subsequent SI or mortality before 28 days or death before discharge 24. In both studies, CSF treatment led to higher absolute neutrophil counts (ANC) persisting for 2 weeks.…”

Section: Colony Stimulating Factorsmentioning

confidence: 85%

The role of colony stimulating factors and immunoglobulin in the prevention and treatment of neonatal infection

Carr

2012

Arch Dis Child Fetal Neonatal Ed

View full text Add to dashboard Cite

“…We followed the schedule specified by Kocherlakota and La Gamma. [1819] The product was infused intravenously and slowly in a single daily dose of 10 μg/kg/day in a 5% dextrose solution over 20-40 min for 3 consecutive days, starting no longer than 48 h after neutropenia was diagnosed. Placebo consisted of an equivalent volume of 5% dextrose.…”

Section: Methodsmentioning

confidence: 99%

Granulocyte colony-stimulating factor for preterms with sepsis and neutropenia: A randomized controlled trial

et al. 2012

View full text Add to dashboard Cite

Background:Bacterial sepsis is one of the major causes of mortality in newborn infants. Mortality increases when sepsis is associated with neutropenia.Materials and Methods:We conducted a prospective, randomized, double-blind, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor on preterm neonates (gestational age (GA) <34 weeks) with sepsis and absolute neutrophil count (ANC) of <1500 cells/mm3. Mortality, duration of Neonatal Intensive Care Unit (NICU) stay, hematological parameters (ANC, platelet count, and total leukocyte count) were compared between the two groups. The GCSF group (n=39) received GCSF intravenously in a single daily dose of 10 μg/kg/day in a 5% dextrose solution over 20-40 min for three consecutive days, while the control group (n=39) received placebo of an equivalent volume of 5% dextrose.Results:Baseline demographic profile among the two groups was comparable. Mortality rate in the GCSF group was significantly lower than in the control group (10% vs. 35%; P<0.05). By day 3 of treatment, ANC in the GCSF group was significantly higher (3521±327) compared to 2094±460 in the control group, with P value being <0.05. Duration of NICU stay also decreased significantly in the GCSF group.Conclusion:The administration of GCSF in preterms with septicemia and neutropenia resulted in lower mortality rates. Further studies are required to confirm our results and establish this adjunctive therapy in neonatal sepsis.

show abstract

A Multicenter, Randomized, Placebo-Controlled Trial of Prophylactic Recombinant Granulocyte-Colony Stimulating Factor in Preterm Neonates with Neutropenia

Cited by 55 publications

References 33 publications

Neonatal Alloimmune Neutropenia

Neonatal Alloimmune Neutropenia

The role of colony stimulating factors and immunoglobulin in the prevention and treatment of neonatal infection

Granulocyte colony-stimulating factor for preterms with sepsis and neutropenia: A randomized controlled trial

Contact Info

Product

Resources

About